Clean Pharmaceutical Manufacturings

Codexis announced an agreement to manufacture 50 grams of small interfering RNA to support a partner’s preclinical program targeting a cardiovascular indication. The supply commitment is intended to provide material for in vivo studies, formulation development, and other preclinical activities that require multi gram to tens of gram quantities. Codexis will produce the material using its ECO Synthesis® enzymatic manufacturing platform under quality standards aligned with downstream development needs. The company describes the engagement as a contract manufacturing arrangement that delivers GMP‑aligned output suitable for nonclinical testing and early formulation work.

The transaction is presented as an example of enzymatic approaches applied to oligonucleotide production, with Codexis highlighting potential advantages in process efficiency, reduced solvent use, and scalability relative to some traditional chemical synthesis routes. The company frames the order as a demonstration of platform applicability across RNA modalities and as a step toward broader commercial supply capabilities for therapeutic oligonucleotides. Observers note that successful delivery of multi gram quantities can support accelerated preclinical timelines and provide a reference case for enzymatic manufacturing in the evolving oligonucleotide supply chain.

Image Credit: